Health Benefits
1. Anti toxic effects
In the investigation of the effect of silymarin on doxorubicin-induced toxicity to the rat kidney, heart, and liver, found that the silymarin group received silymarin (100mg/kg) every other day. In the doxorubicin + silymarin group, silymarin was injected ip at 100 mg/kg dose for 5 days before doxorubicin administration (10 mg/kg, single ip injection) and then continued daily thereafter until euthanization, Doxorubicin caused a significant increase in serum NO levels compared to controls. Silymarin pretreatment group lowered these. Histopathological and electron microscopic examinations of kidney, heart, and liver sections showed doxorubicin to cause myocardial and renal injury which was levv evident in silymarin treated rats, according to "Protective Effects of Silymarin against Doxorubicin-induced Toxicity"by Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M.(1)
2. Hepaprotective effects
In the investigation of the role of curcumin (CUR), silymarin (SILY) and N-acetylcysteine (N-ACET) on hepatotoxicity by ATT drugs using an in vitro model of human hepatocellular carcinoma cell line (HepG2), found that that the presence of hepatoprotective drugs during treatment of HepG2 cells with ATT drugs lowers the hepatotoxic effect of the latter, according to "Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model' by Singh M, Sasi P, Gupta VH, Rai G, Amarapurkar DN, Wangikar PP.(2)
3. Anti Cervical cancer
In the evaluation of the potential action of silymarin against cervical cancer and its mechanism of action, found that Silymarin induced apoptosis through the modulation of Bcl-2 family proteins and activation of caspase 3. Silymarin also inhibited the phosphorylation of Akt with an increase in expression of phosphatase and tensin homolog (PTEN). We also observed that silymarin suppressed C-33A cell invasion and wound-healing migration in a concentration-dependent manner. Western-blot analysis showed that silymarin significantly inhibited the expression of matrix metalloproteinase-9 (MMP-9) in C-33A cells, according to "Silymarin Inhibits Cervical Cancer Cell Through an Increase of Phosphatase and Tensin Homolog" by Yu HC, Chen LJ, Cheng KC, Li YX, Yeh CH, Cheng JT.(3)
4. Anti cancers
In the review of the summarization of the recent investigations and mechanistic studies regarding possible molecular targets of silymarin for cancer prevention, found that the protective effects of silymarin and its major active constituent, silibinin, studied in various tissues, suggest a clinical application in cancer patients as an adjunct to established therapies, to prevent or reduce chemotherapy as well as radiotherapy-induced toxicity. This review focuses on the chemistry and analogues of silymarin, multiple possible molecular mechanisms, in vitro as well as in vivo anti-cancer activities, and studies on human clinical trials, according to "Multitargeted therapy of cancer by silymarin" by Ramasamy K, Agarwal R.(4)
5. Prostate cancer
In the investigation of the stidy of three rat PCA cell lines, namely H-7, I-8, and I-26, were treated with silibinin or silymarin, a crude silibinin-containing preparation, at various doses for varying lengths of time. Cell growth and viability studies were carried out by using hemocytometer and Trypan blue dye exclusion methods, found that silibinin as well as silymarin induce growth inhibition and apoptosis in rat PCA cells. These results form a strong rationale for PCA prevention and therapeutic intervention studies with silibinin and silymarin in animal models, such as the MNU-testosterone rat PCA model, to establish their efficacy and to further define their mechanisms of action under in vivo conditions, according to "Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells" by Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R.(5)
6. Liver cancer
In the assessment of the mechanisms involved in the growth inhibitory effect of silymarin, in humanhepatocellular carcinoma, found that Silymarin inhibited population growth of the hepatocellular carcinoma cells in a dose-dependent manner, and the percentage of apoptotic cells was increased after treatment with 50 and 75 microg/ml silymarin for 24 h. Silymarin treatment increased the proportion of cells with reduced DNA content (sub-G(0)/G(1) or A(0) peak), indicative of apoptosis with loss of cells in the G(1) phase. Silymarin also decreased mitochondrial transmembrane potential of the cells, thereby increasing levels of cytosolic cytochrome c while up-regulating expression of pro-apoptotic proteins (such as p53, Bax, APAF-1 and caspase-3) with concomitant decrease in anti-apoptotic proteins (Bcl-2 and survivin) and proliferation-associated proteins (beta-catenin, cyclin D1, c-Myc and PCNA), according to "Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells" by Ramakrishnan G, Lo Muzio L, Elinos-Báez CM, Jagan S, Augustine TA, Kamaraj S, Anandakumar P, Devaki T.(6)
7. Bladder cancer
In the searching the underlying mechanisms and examining the intravesical efficacy of silibinin, a natural flavonoid in the prevention and treatment of bladder cancer. Human bladder carcinoma cell line 5637, which has the same molecular features of high-risk superficial bladder cancer, was used as the model system in vitro and in vivo, found that oral silibinin suppressed the growth of 5637 xenografts, which was accompanied with the activation of caspase-3, downregulation of survivin, and increased translocation of AIF. Furthermore, intravesical silibinin effectively inhibited the carcinogenesis and progression of bladder cancer in rats initiated by MNU by reducing the incidence of superficial and invasive bladder lesions without any side effects, which was accompanied with proapoptotic effects, according to "Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria" by Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, Wang Z, Zhang D, Xue Y, Chen Y, Zhu G, Wang X, He D.(7)
8. Antioxidants and anti cancers
In the study of the effect of three natural antioxidants curcumin, silymarin and acteoside on AP9-cd (standardized lignan composition from Cedrus deodara) induced cytotoxicity in human leukemia HL-60 cells, found that out of the three antioxidants, curcumin was found to be more potent than acteoside and silymarin in terms of enhancing the apoptotic potential of AP9-cd. These results propose an important role of natural antioxidant as adjuvant to enhance the anticancer potential of AP9-cd and more likely other anti-neoplastic therapeutics, according to "Natural antioxidants synergistically enhance the anticancer potential of AP9-cd, a novel lignan composition from Cedrus deodara in human leukemia HL-60 cells" by Saxena A, Saxena AK, Singh J, Bhushan S.(8)
9. Antimetastatic effects
In the investigation of Silibinin, a popular dietary supplement isolated from milk thistle seed extracts against a variety of cancers, found that detailed mechanistic analyses revealed that silibinin targets signaling molecules involved in the regulation of epithelial-to-mesenchymal transition, proteases activation, adhesion, motility, invasiveness as well as the supportive tumor-microenvironment components, thereby inhibiting metastasis. Overall, the long history of human use, remarkable nontoxicity, and preclinical efficacy strongly favor the clinical use of silibinin against advanced metastatic cancers, according to "Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer" by Deep G, Agarwal R.(9)
10. Gastric cancer
In the determination of the effect of silibinin on TNF-alpha-induced MMP-9 expression in gastric cancer cell lines. MMP-9 mRNA and protein expression was dose-dependently increased by TNF-alpha in SNU216 and SNU668 gastric cancer cells, found that the expression of MMP-9 was significantly increased by CA-MEK overexpression, but not by CA-Akt overexpression. Taken together, we suggest that silibinin down-regulates TNF-alpha- induced MMP-9 expression through inhibition of the MEK/ERK pathway in gastric cancer cells, according to "Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway" by Kim S, Choi MG, Lee HS, Lee SK, Kim SH, Kim WW, Hur SM, Kim JH, Choe JH, Nam SJ, Yang JH, Kim S, Lee JE, Kim JS.(10)
11. Etc.
Recommended E books
Dr. Joseph Mercola's Complete Guide
To Weight Loss, Preventing Diseases, Premature Aging,
And Living Healthy And Longer
For other phytochemicals articles, please visit http://medicaladvisorjournals.blogspot.com/2011/10/phytochemicals-health-benefits.html
other health articles, please visit
http://medicaladvisorjournals.blogspot.com/
Sources
(1) http://www.ncbi.nlm.nih.gov/pubmed/22320977
(2) http://www.ncbi.nlm.nih.gov/pubmed/22318308
(3) http://www.ncbi.nlm.nih.gov/pubmed/22016029
(4) http://www.ncbi.nlm.nih.gov/pubmed/18472213
(5) http://www.ncbi.nlm.nih.gov/pubmed/12386921
(6) http://www.ncbi.nlm.nih.gov/pubmed/19317806
(7) http://www.ncbi.nlm.nih.gov/pubmed/21220495
(8) http://www.ncbi.nlm.nih.gov/pubmed/20932957
(9) http://www.ncbi.nlm.nih.gov/pubmed/20714788
(10) http://www.ncbi.nlm.nih.gov/pubmed/19924065
No comments:
Post a Comment